- Home
- DLPN vs GOVX Comparison
DLPN vs GOVX Comparison
Compare DLPN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- GOVX
- Stock Information
- Founded
- DLPN 1996
- GOVX 2001
- Country
- DLPN United States
- GOVX United States
- Employees
- DLPN N/A
- GOVX N/A
- Industry
- DLPN Other Consumer Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- DLPN Consumer Discretionary
- GOVX Health Care
- Exchange
- DLPN Nasdaq
- GOVX Nasdaq
- Market Cap
- DLPN 16.9M
- GOVX 16.8M
- IPO Year
- DLPN N/A
- GOVX N/A
- Fundamental
- Price
- DLPN $1.55
- GOVX $0.58
- Analyst Decision
- DLPN Strong Buy
- GOVX Strong Buy
- Analyst Count
- DLPN 1
- GOVX 3
- Target Price
- DLPN $5.00
- GOVX $10.67
- AVG Volume (30 Days)
- DLPN 65.9K
- GOVX 1.2M
- Earning Date
- DLPN 11-13-2025
- GOVX 11-11-2025
- Dividend Yield
- DLPN N/A
- GOVX N/A
- EPS Growth
- DLPN N/A
- GOVX N/A
- EPS
- DLPN N/A
- GOVX N/A
- Revenue
- DLPN $51,257,243.00
- GOVX $6,143,044.00
- Revenue This Year
- DLPN $9.05
- GOVX N/A
- Revenue Next Year
- DLPN $15.42
- GOVX N/A
- P/E Ratio
- DLPN N/A
- GOVX N/A
- Revenue Growth
- DLPN 4.84
- GOVX 1943.07
- 52 Week Low
- DLPN $0.75
- GOVX $0.43
- 52 Week High
- DLPN $1.78
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- DLPN 60.42
- GOVX 45.32
- Support Level
- DLPN $1.35
- GOVX $0.54
- Resistance Level
- DLPN $1.68
- GOVX $0.61
- Average True Range (ATR)
- DLPN 0.13
- GOVX 0.04
- MACD
- DLPN 0.00
- GOVX 0.01
- Stochastic Oscillator
- DLPN 67.44
- GOVX 48.45
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.